Physician profile
Clarylee Octaviani
NPI 1144249624
$5,701.33
in general payments reported to CMS, 2019-2025
27 companies · $3,353 in 2025
The $3,353 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2021: $20.32 · 2022: $62.68 · 2023: $18.34 · 2024: $2,128 · 2025: $3,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,143 · Education: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,142.72 |
| Education | $355.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $890.84 | 2024-2025 | Acthar, Terlivaz |
| Amgen INC. | $819.59 | 2024-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $425.17 | 2024-2025 | Filspari |
| Calliditas Therapeutics US INC. | $392.49 | 2024-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $337.62 | 2024-2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $327.93 | 2024-2025 | Jynarque, Voyxact |
| Ardelyx, INC. | $292.75 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $226.50 | 2021-2025 | |
| Renalytix Ai, INC. | $217.76 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Novartis Pharmaceuticals Corporation | $211.63 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $209.07 | 2022-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $165.60 | 2024-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.85 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $146.66 | 2024-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $127.97 | 2025 | Veltassa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $119.82 | 2019 | |
| Scpharmaceuticals INC. | $111.24 | 2025 | |
| Corcept Therapeutics | $99.56 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $88.54 | 2024-2025 | Shingrix, Arexvy, Benlysta |
| Lilly USA, LLC | $78.06 | 2024-2025 | Jardiance |
| Apellis Pharmaceuticals, INC. | $65.00 | 2025 | Empaveli |
| Vantive US Healthcare LLC | $55.28 | 2025 | Renal - Pd |
| Kyowa Kirin, INC. | $46.55 | 2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $22.52 | 2024 | Ultomiris |
| Ascendis Pharma Endocrinology INC | $22.21 | 2025 | Yorvipath |
| Mannkind Corporation | $20.68 | 2025 | |
| Horizon Therapeutics Plc | $18.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarylee Octaviani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.